HDAC6 and acute kidney injury: Selective inhibition of HDAC6 activity by a small-molecule compound N-hydroxy- 4-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)-amino)phenoxy)butanamide (23bb) might be a promising strategy for the treatment of AKI.